Australian Industry Gets Price Rises To Offset Cost Of New Anti-Shortage Rules
Australia’s health department has issued guidance giving more details of the requirement to hold minimum levels of stocks of specified medicines from mid-2023.
You may also be interested in...
Measures just introduced by the Therapeutic Goods Administration are intended to ensure the ongoing and reliable supply of important medicines and to improve the information in the drug shortages database.
The Australian government has committed to cutting co-payments for medicines listed on its pharmaceutical benefits scheme by 30%, a move which has been praised by the country’s Generic and Biosimilar Medicines Association.
Hot on the heels of Australia’s plan to overhaul the National Medicines Policy comes a new deal with the pharmaceutical industry to make new drugs available as soon as possible after approval and get patients more closely involved in reimbursement processes.